{
    "id": 25746,
    "fullName": "PAK1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PAK1 positive indicates the presence of the PAK1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5058,
        "geneSymbol": "PAK1",
        "terms": [
            "PAK1",
            "alpha-PAK",
            "IDDMSSD",
            "p65-PAK",
            "PAKalpha"
        ]
    },
    "variant": "positive",
    "createDate": "11/15/2016",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9256,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung papillary adenocarcinoma cell line harboring EGFR wild-type and expressing PAK1 demonstrated resistance to Iressa (gefitinib) in culture (PMID: 27178741).",
            "molecularProfile": {
                "id": 26797,
                "profileName": "EGFR wild-type PAK1 pos"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 5588,
                "name": "lung papillary adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26792,
            "profileName": "PAK1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26796,
            "profileName": "EGFR mut PAK1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26797,
            "profileName": "EGFR wild-type PAK1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}